TY - JOUR
T1 - The Association of Female Reproductive Factors with Glaucoma and Related Traits
T2 - A Systematic Review
AU - Madjedi, Kian M.
AU - Stuart, Kelsey V.
AU - Chua, Sharon Y.L.
AU - Foster, Paul J.
AU - Strouthidis, Nicholas G.
AU - Luben, Robert N.
AU - Warwick, Alasdair N.
AU - Kang, Jae H.
AU - Wiggs, Janey L.
AU - Pasquale, Louis R.
AU - Khawaja, Anthony P.
N1 - Funding Information:
A.N.W.: Financial Support – Wellcome Trust (grant 220558/Z/20/Z).
Funding Information:
J.L.W.: Consultant – Aerpio, Allergan, Maze, Editas Medicine, and Regenxbio Inc.; Financial Support – NIH NEI (grants R01 EY015473, R01 EY032559), The Glaucoma Foundation, Aerpio, Challenge Grant from Research to Prevent Blindness, New York City, and ARVO Foundation David Epstein Award.
Funding Information:
L.R.P.: Consultant – Eyenovia, Skye Biosciences Inc., and Twenty Twenty; Financial Support – NIH NEI (grants R01 EY015473, R01 EY032559), The Glaucoma Foundation, and Challenge Grant from Research to Prevent Blindness, New York City.
Funding Information:
K.V.S.: Financial Support - UCL Overseas Research Scholarship, Fight for Sight (1956A), and The Desmond Foundation.
Funding Information:
The author(s) have made the following disclosure(s): A.P.K.: Consultant – Aerie, Allergan, Google Health, Novartis, Reichert Inc., Santen Pharmaceutical Co., Ltd., and Thea Pharma Inc.; Support – UK Research and Innovation Future Leaders Fellowship (Medical Research Council MR/T040912/1), Alcon Research Institute Young Investigator Award, Lister Institute Fellowship, and Moorfields Eye Charity Career Development Fellowship.
Funding Information:
The author(s) have made the following disclosure(s): A.P.K.: Consultant – Aerie, Allergan, Google Health, Novartis, Reichert Inc., Santen Pharmaceutical Co., Ltd., and Thea Pharma Inc.; Support – UK Research and Innovation Future Leaders Fellowship (Medical Research Council MR/T040912/1), Alcon Research Institute Young Investigator Award, Lister Institute Fellowship, and Moorfields Eye Charity Career Development Fellowship. L.R.P.: Consultant – Eyenovia, Skye Biosciences Inc., and Twenty Twenty; Financial Support – NIH NEI (grants R01 EY015473, R01 EY032559), The Glaucoma Foundation, and Challenge Grant from Research to Prevent Blindness, New York City. J.L.W.: Consultant – Aerpio, Allergan, Maze, Editas Medicine, and Regenxbio Inc.; Financial Support – NIH NEI (grants R01 EY015473, R01 EY032559), The Glaucoma Foundation, Aerpio, Challenge Grant from Research to Prevent Blindness, New York City, and ARVO Foundation David Epstein Award. P.J.F.: Consultant – Alphasights, GLG, Google Health, Guidepoint, PwC, and Santen Pharmaceutical Co., Ltd.; Financial Support – Alcon. A.N.W.: Financial Support – Wellcome Trust (grant 220558/Z/20/Z). J.H.K.: Financial Support – National Institutes of Health. R.N.L.: Financial Support – Moorfields Eye Charity Springboard Award. K.V.S.: Financial Support - UCL Overseas Research Scholarship, Fight for Sight (1956A), and The Desmond Foundation. The funding organizations had no role in the design or conduct of this research. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided.
Publisher Copyright:
© 2022 American Academy of Ophthalmology
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Topic: This systematic review summarizes evidence for associations between female reproductive factors (age at menarche, parity, oral contraceptive [OC] use, age at menopause, and postmenopausal hormone [PMH] use) and intraocular pressure (IOP) or open-angle glaucoma (OAG). Clinical Relevance: Understanding the associations between female reproductive factors and glaucoma may shed light on the disease pathogenesis and aid clinical prediction and personalized treatment strategies. Importantly, some factors are modifiable, which may lead to new therapies. Methods: Two reviewers independently extracted articles in MEDLINE, Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials databases to identify relevant studies. Eligibility criteria included studies with human subjects aged > 18 years; a measured outcome of either IOP or OAG; a cohort, case-control, cross-sectional, or randomized controlled trial design; a reported measure of association, such as the hazard ratio, relative risk, odds ratio, or mean difference, with an associated confidence interval; and a measured exposure of at least 1 of the following variables: age at menarche, parity, OC use, age at menopause, or PMH use. Results: We included a total of 27 studies. Substantial differences in study designs, exposure and treatment levels, treatment durations, and variable reporting precluded a meaningful quantitative synthesis of the identified studies. Overall, relatively consistent associations between PMH use and a lower IOP were identified. Estrogen-only PMH use may be associated with lower OAG risk, which may be modified by race. No significant associations were found with combined estrogen-and-progesterone PMH use. No strong associations between parity or age at menarche and glaucoma were found, but a younger age at menopause was associated with an increased glaucoma risk, and adverse associations were identified with a longer duration of OC use, though no overall association with OC use was found. Conclusions: The association between PMH use and lower IOP or OAG risk is a potentially clinically relevant and modifiable risk factor and should be investigated further, although this needs to be interpreted in the context of a high risk of bias across included studies. Future research should examine associations with IOP specifically and how the relationship between genetic factors and OAG risks may be influenced by female reproductive factors.
AB - Topic: This systematic review summarizes evidence for associations between female reproductive factors (age at menarche, parity, oral contraceptive [OC] use, age at menopause, and postmenopausal hormone [PMH] use) and intraocular pressure (IOP) or open-angle glaucoma (OAG). Clinical Relevance: Understanding the associations between female reproductive factors and glaucoma may shed light on the disease pathogenesis and aid clinical prediction and personalized treatment strategies. Importantly, some factors are modifiable, which may lead to new therapies. Methods: Two reviewers independently extracted articles in MEDLINE, Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials databases to identify relevant studies. Eligibility criteria included studies with human subjects aged > 18 years; a measured outcome of either IOP or OAG; a cohort, case-control, cross-sectional, or randomized controlled trial design; a reported measure of association, such as the hazard ratio, relative risk, odds ratio, or mean difference, with an associated confidence interval; and a measured exposure of at least 1 of the following variables: age at menarche, parity, OC use, age at menopause, or PMH use. Results: We included a total of 27 studies. Substantial differences in study designs, exposure and treatment levels, treatment durations, and variable reporting precluded a meaningful quantitative synthesis of the identified studies. Overall, relatively consistent associations between PMH use and a lower IOP were identified. Estrogen-only PMH use may be associated with lower OAG risk, which may be modified by race. No significant associations were found with combined estrogen-and-progesterone PMH use. No strong associations between parity or age at menarche and glaucoma were found, but a younger age at menopause was associated with an increased glaucoma risk, and adverse associations were identified with a longer duration of OC use, though no overall association with OC use was found. Conclusions: The association between PMH use and lower IOP or OAG risk is a potentially clinically relevant and modifiable risk factor and should be investigated further, although this needs to be interpreted in the context of a high risk of bias across included studies. Future research should examine associations with IOP specifically and how the relationship between genetic factors and OAG risks may be influenced by female reproductive factors.
KW - Estrogen
KW - Glaucoma
KW - HRT
KW - IOP
KW - POAG
UR - http://www.scopus.com/inward/record.url?scp=85139208666&partnerID=8YFLogxK
U2 - 10.1016/j.ogla.2022.06.003
DO - 10.1016/j.ogla.2022.06.003
M3 - Article
C2 - 35691565
AN - SCOPUS:85139208666
VL - 5
SP - 628
EP - 647
JO - Ophthalmology. Glaucoma
JF - Ophthalmology. Glaucoma
SN - 2589-4196
IS - 6
ER -